Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706, Lenvatinib, and AG Regimen in Advanced Pancreatic Cancer
NCT07110064Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in pancreatic cancer (PC). Started Sep 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07110064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110064.